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1. Introduction
The adult retina is a neural tissue with high metabolism and the highest oxygen consumption
per unit weight of all human tissues. Therefore, the choroid, the most vascular layer of the eye
also nourishing the retina, has one of the highest blood-flow rates in the body, 800 – 1000
mL/100 g tissue/min [1]. In healthy adults this delicate ocular vascular system is maintained
and controlled by the balance between the angiogenic factors and angiogenic inhibitors [2].
Age-related macular degeneration (AMD) is the result of complex interactions between lipo‐
fuscinogenesis, drusenogenesis, and inflammation which can lead to choroidal neovasculari‐
zation(CNV)[3]. An imbalance between the proangiogenic vascular endothelial growth
factor (VEGF) and the antiangiogenic pigment epithelium-derived factor (PEDF)[3-4], plays
a major role in the pathogenesis of the disease.
Inhibitors of VEGF represent a relatively new treatment for CNV. These agents include the
Macugen (aptamer) which was almost completely abandoned with the introduction of the
efficient FDA approved Ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA),
in addition to others such as the Bevacizumab (Avastin; Genentech, Inc), and the new FDA
approved drug Eylea(VEGF Trap Eye Regeneron, Tarrytown, NY, USA).
2. Vascular endothelial growth factors
Vascular endothelial growth factor (VEGF) plays a key role in ocular angiogenesis and vas‐
cular permeability. Several VEGF family members have been discovered (VEGF-A, B, C, D
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and PIGF). These isoforms of VEGF have different effects in ocular pathologies and may dif‐
fer in their neuroprotective abilities [5, 6]. RPE and Müller cells are the major sources of
VEGF and they exert their effects through multiple receptors that are mostly expressed on
endothelial cells and are also found on monocytes and macrophages [7].
VEGF-A, has been most strongly associated with angiogenesis and thus consists the target of
most anti-VEGF treatments [8, 9]. VEGF-A signals through two receptor tyrosine kinases,
VEGFR1 and VEGFR2, and is induced by hypoxia, unlike other VEGF isoforms [7, 10].
Alternative exon splicing of the human VEGF-A gene results in at least four major biologi‐
cally active isoforms, containing 121, 165, 189, and 208 aminoacids (five more are VEG‐
FA-145, VEGFA-162, VEGFA-165b, VEGFA-183, and VEGFA-206) [11].
Different VEGF-A isoforms may have different functions in ocular diseases.
VEGF 121 appears to be essential for normal retinal vascular function [12-13], and VEG‐
FA-165 is the predominant isoform in the human eye. It isa heparin-binding, homodimeric,
45-kDa glycoprotein that is predominantly secreted, although a substantial fraction is bound
to the cell surface and to the extracellular matrix[13-14].It appears to be the isoform respon‐
sible for pathological ocular neovascularization.
Both isoforms are found in CNV tissue excised from patients with AMD.
In autopsy studies, VEGF levels were found to be elevated in the retinal pigment epithelium
(RPE) and choroidal blood vessels within the macular area of eyes with AMD [15].
In summary VEGF-A acts through various pathways which result in promoting pathologic
neovascularization:
• It stimulates angiogenesis by being a potent endothelial cell mitogen [10-11].
• It sustains endothelial survival by inhibiting apoptosis [10-12].
• VEGF is a chemo-attractant for endothelial cell precursors, promoting their differentia‐
tion [12-13].
• It is a powerful agonist of vascular permeability which is particularly important in CNV.
Increased vascular permeability in response to VEGF may be due to formation of fenes‐
trations in microvascular endothelium [12-14].
• Leukocytes may amplify the effects of VEGF via their own secretion of VEGF. Further‐
more, VEGF’s pro-inflammatory activity, predominantly through the 164 isoform, con‐
tributes to pathological ocular neovascularization [14]. It is therefore a crucial target in
combating neovascular and ischemic eye diseases such as: choroidal neovascularization,
macular edema secondary to diabetic retinopathy (DME) or retinal vein occlusion and ret‐
inal neovascularisation that may develop in retinal vein occlusion (RVO) or diabetic retin‐
opathy (DR).
Several anti-VEGF drugs have been studied and have been shown to be effective. However,
effective, long-term drug-delivery remains a challenge. Two multi-center, randomized con‐
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trolled trials comparing the two most commonly drugs available were published recently. A
summary of the available drugs (table 1), their mechanism of action and results from large
multicenter trials evaluating their efficacy and safety is presented below.
3. Anti VEGF drugs
3.1. Pegaptanib sodium (Macugen) – OSI/Eyetech
This intravitreal RNA aptamer drug was the first anti-VEGF drug approved by the FDA in
2004 for use in neovascular AMD (nvAMD). It targets VEGFA-165[11]Its efficacy and safety
were evaluated in the large VISION trial [16, 17].
Patients with different types of sub foveal CNV secondary to AMD were randomized into
four groups. Three groups received an intravitreal injection of pegaptanib sodium at a dose
of 0.3mg, 1.0mg, 3.0mg to one eye respectively. The injection was given every 6 weeks for a
period of 48 weeks in total. The forth group was the control group and subjects in this group
received a sham injection every 6 weeks. Primary outcome was mean change in visual acui‐
ty from baseline.
Results from a combined analysis showed that for all three doses of pegaptanib (P<0.001 for
the comparison of 0.3 mg with sham injection; P<0.001 for the comparison of 1.0 mg with
sham injection; and P=0.03 for the comparison of 3.0 mg with sham injection) there was a
significant difference between the patients receiving treatment and those receiving a sham
injection. In the group dosed with pegaptanib 0.3 mg, 70 percent of patients lost fewer than
15 letters of visual acuity (VA), as compared with 55 percent among the controls (P<0.001).
The risk of severe loss of VA (loss of 30 letters or more) was reduced from 22 percent in the
sham-injection group to 10 percent in the group receiving 0.3 mg of pegaptanib (P<0.001).
More patients receiving pegaptanib (0.3 mg), as compared with sham injection, maintained
their VA or gained acuity (33 % vs. 23%; P=0.003). As early as six weeks after beginning ther‐
apy with the study drug, and at all subsequent points, the mean visual acuity among pa‐
tients receiving 0.3 mg of pegaptanib was better than in those receiving sham injections
(P<0.002). During the second year, patients initially assigned to pegaptanib were re-random‐
ized (1:1) to continue or discontinue therapy for 48 additional weeks (8 injections). Those ini‐
tially assigned to sham were re-randomized to continue sham, discontinue sham, or receive
1 of 3 pegaptanib doses. The proportion of patients who lost more than 15 letters or more in
vision between week 52 to week 96 was double (14 vs 7%), if treatment was discontinued
compared to those who continued to receive pegaptanib injections. This suggests that there
is a more favorable outcome when continuing treatment for at least two years [18].The Pe‐
gaptanib was found safe and there was no significant difference in serious systemic adverse
events or severe ocular inflammation, cataract or glaucoma between the pegaptanib treated
groups and the sham treated groups [16, 17].
The VA results of the VISION study are clearly inferior to those of the MARINA and AN‐
CHOR studies evaluating the efficacy of intravitreal ranibizumab for nvAMD (detailed lat‐
Anti VEGF Agents for Age Related Macular Degeneration
http://dx.doi.org/10.5772/54198
er). However, VA efficacy is only one of the clinical considerations that must be taken into
account. The safety profile of the drug is not less important. The Macugen was proven to be
safe in the VISION study as well as in the smaller study by N. Feucht et al. [19]; in both
studies no relevant systemic or ocular adverse effects were noted. Cardiovascular incidents
and overall mortality in the Pegaptanib sodium group were comparable to those of the
sham injection group.
Thus, we can conclude that stable vision can be achieved with repeated injections as fre‐
quent as every 6 weeks with pegaptanib. This treatment may still be taken into considera‐
tion especially in subjects suffering from cardiovascular diseases.
3.2. Ranibizumab (Lucentis) - Genentech
Ranibizumab is a small 48kDa recombinant humanized monoclonal antibody fragment. Its
small molecular weight enables it to penetrate the inner limiting membrane and reach the
subretinal space when injected intravitreally [5,8-9]. It binds all biologically active isotypes
of VEGF with high affinity. The half-life of ranibizumab is 2 – 4 days [5, 8], resulting in a
rapid systemic clearance and good systemic safety profile.
FDA has approved the use of ranibizumab for treatment of all angiographic subtypes of
subfoveal CNV due to AMD. The phase III MARINA trial evaluated the efficacy and safety
of ranibizumab for the treatment of minimally classic or occult with no classic CNV associat‐
ed with AMD. This 2-year, prospective randomized, double-masked, sham-controlled trial
enrolled 716 patients. Patients were randomized in a 1 : 1 : 1 ratio to receive intravitreal rani‐
bizumab at a dose of either 0.3 mg or 0.5mg or sham injection monthly in one eye for 2 years
[9]. The primary outcome was the proportion of patients losing fewer than 15 letters from
baseline visual acuity at 12 months.
At 24 months, 92% of patients who received 0.3 mg of ranibizumab and 90% of patients who
received 0.5 mg ranibizumab lost fewer than 15 letters, compared with 52.9% in the sham
group. The proportion of patients who gained at least 15 letters on the Early Treatment of
Diabetic Retinopathy Study (ETDRS) chart from baseline to 24 months was 33.3% in the
0.5mg group, 26.1% in the 0.3mggroup, and 3.8% in the sham group. The mean change in
ETDRS VA from baseline to 24 months was a gain of 6.6 letters in the 0.5mg group, a gain of
5.4 letters in the 0.3mg group, and a loss of 14.9 letters in the sham-injection group [9].
The ANCHOR study evaluated the efficacy of Ranibizumab for treatment of Predominantly
Classic sub foveal CNV due to AMD. The ANCHOR trial was a multicenter, randomized
double-blind trial that enrolled 423 patients to compare the efficacy and safety of ranibizu‐
mab vs PDT with verteporfin[20]. Patients were assigned randomly to receive either 0.3 or
0.5mg of ranibizumab plus sham verteporfin, or sham intravitreal injection plus active verte‐
porfin therapy. Ranibizumab or sham intravitreal injections were given monthly, and the
verteporfin or sham was administered on day 0 and then as needed at months 3,6, 9, and 12.
At  12  months,  94.3% of  patients  in  the  0.3mg group and96.4% in  the  0.5mg group lost
fewer than 15 letters  from baseline compared with 64.3% in the verteporfin group.  The
proportion  of  patients  who  gained  at  least  15  letters  from  baseline  to  12  months  was
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40.3% in the 0.5mg group, 35.7%in the 0.3mg group, and 5.6% in the verteporfin group.
The mean change in VA from baseline to 12months was a gain of 8.5 letters in the 0.3mg
group, a gain of11.3 letters in the 0.5mg group, and a loss of 9.5 letters in the vertepor‐
fin group [20].  Rates of  serious ocular or systemic adverse events were low in both the
MARIMA and the ANCHOR trials[20].
Both studies showed no difference in the percentage of patients losing 15 letters in vision
between the 0.3 and 0.5mg. However, the 0.5 mg was statistically significant superior to the
0.3 mg in achieving 15 letters or more in vision. This difference in favor of the 0.5 mg led to
its approval by the FDA, and the routine use of 0.5 mg ranibizumab.
The PIER study [21] evaluated the efficacy of 3 consecutive monthly injections of ranibi‐
zumab followed by fixed re-treatments  only  every 3  months.  Mean changes  from base‐
line VA at 12 months were -16.3, -1.6, and -0.2 letters loss for the sham, 0.3 mg, and 0.5
mg groups,  respectively  (P  <  or  =.0001,  each  ranibizumab dose  vs  sham).  Ranibizumab
reduced the growth and leakage from the CNV. However,  the treatment effect achieved
following  the  first  3  consecutive  injections  declined  in  the  ranibizumab  groups  during
quarterly dosing (e.g., at three months the mean changes from baseline VA was a gain of
2.9  and 4.3  letters  for  the 0.3  mg and 0.5  mg doses,  respectively).  Results  of  subgroups
analyses of mean change from baseline VA at 12 months by baseline age, VA, and lesion
characteristics were consistent with the overall results. Overall, in this study, the propor‐
tion of  gainers of  more than three lines was significantly lower than in MARINA or in
ANCHOR trials,  and this  is  due to  the  fact  that  following the  first  3  consecutive  injec‐
tions patients were shifted to a significant less frequent dosing of quarterly injections in‐
stead of monthly.
The EXCITE study evaluated the efficacy and safety of monthly versus quarterly ranibizu‐
mab treatment in nvAMD [22]. Patients were randomized (1:1:1) to 0.3 mg quarterly, 0.5 mg
quarterly, or 0.3 mg monthly doses of ranibizumab. Treatment comprised of a loading phase
(3 consecutive monthly injections) followed by a 9-month maintenance phase (either month‐
ly or quarterly injection).In contrast to the PIER study in which patients were examined and
injected only every 3 months following the first 3 consecutive monthly injections, in the EX‐
CITE study, patients were followed monthly, but in the 2 quarterly groups they could re‐
ceive an injection only every 3 months. BCVA increased from baseline to month 12 by 4.9,
3.8, and 8.3 letters in the 0.3 mg quarterly (104 patients), 0.5 mg quarterly (88 patients), and
0.3 mg monthly (101 patients) dosing groups, respectively. The noninferiority of a quarterly
regimen was not achieved with reference to 5.0 letters, meaning dosing with ranibizumab
only every 3 months is inferior than dosing every month, and results in a significant less fa‐
vorable final visual outcome. The safety profile was similar to that reported in prior ranibi‐
zumab studies.
Following the results of the PIER and EXCITE study it can be concluded that monthly injec‐
tions is definitely superior to quarterly injections, and that the quarterly regimen should not
be applied.
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3.3. Bevacizumab (Avastin) - Genentech
This drug is a full-length recombinant humanized monoclonal antibody (149kDa).It binds to
all VEGF-A isoforms. whereas Ranibizumab has only one binding site to VEGF, bevacizu‐
mab has two. Bevacizumab in addition has a longer acting effect in-vitro; however, it may
penetrate less effectively the retina [23-26]. Its half life time in the vitreous is approximately
8-10 days [24-25].
It was first approved by the FDA for metastatic colorectal cancer and is used off-label in oc‐
ular disease. Although systemic administration of bevacizumab was shown to be associated
with increased systemic cardiovascular adverse events, these appear to be rare following in‐
travitreal administration [8, 24].
Many ophthalmologists until recently offered intravitreal bevacizumab to nvAMD patients
based on multiple forms of evidence: results from several retrospective case series,[27-30]
extrapolation from the outcomes reported in the MARINA and ANCHOR studies, the struc‐
tural similarity between ranibizumab and bevacizumab, and mostly the clinical experience
of rapid resolution of morphological abnormalities on optical coherence tomography (OCT)
and fluorescein leakage from CNV after treatment with bevacizumab.
However, treatment with bevacizumab can nowdays be based on the 2-year results of the
Comparison of Age-Related Macular Degeneration Treatment Trial (CATT) and one year re‐
sults of IVAN study (Inhibit VEGF in Age-related choroidal Neovascularisation)which com‐
pared the efficacy of bevacizumab and ranibizumab for nvAMD and will be discussed in
detail later in this chapter.
3.4. Aflibercept (VEGF trap)
VEGF Trap-Eye (EYLEA; Regeneron, Tarrytown, NY, USA) (VTE) is a soluble fusion pro‐
tein  consisting  of  2  extracellular  cytokine  receptor  domains  and  a  human  Fc  region  of
immunoglobulin  G  (IgG).  This110kDa  soluble  receptor  binds  with  high  affinity  to  all
VEGFA  isoforms  and  VEGF  B,  and  not  to  VEGF-C  and  D  [5].  The  binding  affinity  of
VEGF  Trap  to  VEGF  is  10  times  higher  than  bevacizumab.  The  2mg  dose  of  VTE  at
83days has been proven to have a similar biologic activity to ranibizumab at 30 days [5,
31].  The CLEAR-IT is a phase II  trial,  which was recently published and evaluated ana‐
tomic outcomes and VA, injection frequency, and safety. The study consisted of 2 phas‐
es;  the  first  was  a  12-week  fixed  dosing  period  followed  by  an  as-needed  (PRN)
treatment  phase  to  week  52  with  VEGF  Trap-Eye  for  nvAMD  [31].  Patients  were  ran‐
domly assigned to 1 of 5 intravitreal VEGF Trap-Eye treatment groups: 0.5 mg or 2 mg
every 4 weeks or 0.5,  2,  or 4 mg every 12 weeks during the fixed-dosing period (weeks
1-12).  From weeks  16  to  52,  patients  were  evaluated  monthly  and  were  retreated  PRN
with their  assigned dose (0.5,  2,  or  4  mg).  The decrease in CR/LT (central  retinal/lesion
thickness)  at  week  12  versus  baseline  remained significant  at  weeks  12  to  52  (-130  μm
from  baseline  at  week  52)  and  CNV  size  regressed  from  baseline  by  2.21  mm2at  48
weeks.  After  achieving  a  significant  improvement  in  BCVA during  the  12-week-  fixed-
dosing  phase  for  all  groups  combined,  PRN  dosing  for  40  weeks  maintained  the  im‐
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provement in BCVA to 52 weeks (5.3-letter gain; P<0.0001). The robust improvement and
consistent maintenance of VA mainly occurred in patients initially dosed with 2 mg ev‐
ery 4 weeks for 12 weeks, demonstrating a gain of 9 letters at 52 weeks. Overall, a mean
of  2  injections  was  administered  after  the  12-week  fixed-dosing  phase,  and  the  mean
time to first reinjection was 129 days; 19% of patients received no injections and 45% re‐
ceived 1 or 2 injections. Treatment with VEGF Trap-Eye was generally safe and well tol‐
erated,  with  few  ocular  or  systemic  adverse  events.  They  concluded  that  PRN  dosing
with VEGF Trap-Eye at weeks 16-52 maintained the significant anatomic and visual im‐
provements established during the 12-week fixed-dosing phase with a low need for re-in‐
jections.  Repeated  dosing  with  VEGF  Trap-Eye  was  well  tolerated  over  52  weeks  of
treatment.
VIEW1 was a phase III non-inferiority trial conducted in North America that randomized
1217 patients to VTE 0.5 mg monthly dosing (0.5q4wk), VTE 2 mg monthly (2q4wk),VTE 2
mg every two months following 3 initial monthly doses (2q8wk), or ranibizumab 0.5mg
monthly (Rq4wk). The primary endpoint was the proportion of patients who lost fewer than
15 ETDRS letters from baseline to week 52 [32].
Secondary endpoints included mean change in BCVA at week 52. The percentage of partici‐
pants in the Rq4wk, 0.5q4wk, 2q4wk, and 2q8wk treatment arms who gained at least 15 let‐
ters in vision were: 31%,25%, 38%, and 31%, respectively.
The  proportions  of  patients  maintaining  vision  at  52  weeks  were  94.4%,  95.9%,  95.1%,
and 95.1% for  Rq4wk,  0.5q4wk,  2q4wk,  and 2q8wk,  respectively.  All  VTE groups  were
noninferior to ranibizumab. Mean improvement from baseline to week 52 in ETDRS let‐
ter  score  was  8.1,  6.9,  10.9,  and 7.9  letters  for  Rq4wk,  0.5q4wk,  2q4wk,  and 2q8wk,  re‐
spectively.
There was a small significant difference in visual improvement at 52 weeks, between the
2q4wk and the Rq4weeks in favor of  the 2q4weeks,  however this  was not found in the
parallel VIEW 2 trial that will be discussed later. Differences between other VTE groups
and Rq4wk were nonsignificant.  The difference in the mean reduction in central  retinal
thickness  was  not  significant  among  the  groups.  The  incidence  of  adverse  events  was
similar across all treatments, with no increase in blood pressure noted.
Overall, dosing monthly or every two months with VTE was non-inferior to monthly ranibi‐
zumab and was well tolerated [32]. The VIEW2 study was a parallel study to VIEW 1 that
enrolled 1240 patients from Europe, Latin America, Asia, and Australia and yielded similar
results [33]. However, minor differences exist. In the VIEW 2 study there was no statistically
significant difference between all treatment arms in ETDRS letter score at week 52, and un‐
like VIEW1 the 2q4wk group was not superior to Lucentis.
The VIEW 1 and VIEW 2 results demonstrated non-inferior efficacy of VTE 2mg dosed at a
fixed regimen every 8 weeks compared to ranibizumab 0.5mg dosed every 4 weeks. The EY‐
LEA was approved by the FDA for injection every 8 weeks for nvAMD, and therefore may
lower the injection burden on the patient as well as the medical system.
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4. Different regimens for Bevacizumab and Ranibizumab
4.1. Ranibizumab: As-needed regimen
Numerous studies evaluated the effect of PRN intravitreal ranibizumab for the treatment of
nvAMD.
The Prospective OCT Imaging of Patients with nvAMD Treated with Intraocular Ranibizu‐
mab (PrONTO) study was the first open-label, prospective, uncontrolled study to investi‐
gate a variable-dosing of intravitreal ranibizumab over two years [34]. Thirty-seven patients
received 3 consecutive monthly injections of 0.5 mg ranibizumab and were then followed
monthly and re-treated if there was an increase in OCT central retinal thickness (CRT) of at
least 100 microns or a loss of BCVA of 5 letters or more. During the second year, the retreat‐
ment criteria were amended to include re-treatment if any qualitative increase in the amount
of fluid was detectedon OCT. At 24 months (end of 2 years study), mean VA improved by
11letters with an average of 9.9 injections In the PrONTO study therefore we can conclude
that VA outcomes were nearly comparable with those reported in the MARINA and AN‐
CHOR, but these results were achieved with less than half number of intravitreal injections
given in the MARINA and ANCHOR[34].
The SUSTAIN trial was a phase III multicenter open-label single arm study that assessed the
safety and efficacy of ranibizumab in patients with sub foveal CNV secondary to AMD us‐
ing a dosing regimen individualized to patient characteristics. 513 patients who were either
ranibizumab treatment –naïve (69 patients) or had completed treatment with ranibizumab
or verteporfin PDT in the ANCHOR trial participated in this study [35].
Patients received three consecutive monthly injections of ranibizumab 0.3mg (or 0.5mg for
the ANCHOR patients) (the “loading phase”), followed by monthly monitoring visits. Fur‐
ther treatment was administered if VA decreased by >5 letters or if CRT increased by >100
μm. Compared with baseline, mean VA at month 12 increased by approximately 7 letters.
VA reached a maximum level after the first 3 monthly injections, decreased slightly when
shifting to PRN during the next 2 to 3 months and was then sustained throughout the treat‐
ment period. Over 12 months, the mean standard deviation (SD) number of ranibizumab in‐
jections received by the 69 ranibizumab naıve patients was 5.3 (±2.2), including the three
“loading” injections. This study demonstrated that flexible, guided dosing with fewer injec‐
tions and monthly monitoring can be efficient and result in good visual outcome in at least
some patients [35].
The SAILOR (Safety Assessment of IntravitrealLucentis for age-related macular degenera‐
tion) study, a Phase IIIb study of Lucentis for patients with all subtypes of new or recurrent
active sub fovealCNV due to AMD, was a twelve-month randomized (cohort 1) or open-la‐
bel (cohort 2) multicenter clinical trial [36]. 4300 subjects were recruited. Cohort 1 subjects
were randomized 1:1 to receive 0.3 mg (n = 1169) or 0.5 mg (n = 1209) intravitreal ranibizu‐
mab for 3 monthly loading doses, followed by monthly visits. Cohort 2 subjects received 1
single open-label 0.5 mg intravitreal ranibizumab, and than continue the monthly follow up
visits. Those groups were stratified by AMD treatment history (treatment-naïve vs. previ‐
Age-Related Macular Degeneration - Etiology, Diagnosis and Management - A Glance at the Future170
ously treated). Cohort 1 subjects were retreated on the basis of OCT or BCVA criteria. Co‐
hort 2 subjects (n = 1922) received an initial single intravitreal dose of 0.5 mg ranibizumab
and were retreated at physician discretion. Safety was evaluated at all visits. It concluded
that Intravitreal ranibizumab was safe and well tolerated in a large population of subjects
with neovascular AMD. Ranibizumab had a beneficial effect on VA but quarterly visits were
insufficient to monitor and capture disease progression [36] If a fixed regimen of monthly
injections is not applied, than monthly visits are recommended and injectios performed as
needed usually guided by visual acuity and OCT findings.
The HORIZON study was an open-label multicenter extension study that included 853 pa‐
tients (600 had been previously treated with ranibizumab initially, 184 had crossed over to
treatment with ranibizumab, and 69 had not been treated with ranibizumab) who had com‐
pleted one of the three 2-year, randomized, controlled trials of monthly intravitreal ranibi‐
zumab treatment (MARINA, ANCHOR or FOCUS trial). Of the 853 patients, two-year VA
data were available for 384 [37]. These patients could receive 0.5 mg ranibizumab at 30-day
or longer intervals as needed. Of the patients who received initial treatment with ranibizu‐
mab during the ANCHOR, MARINA, and FOCUS trials, there was a mean 10.2-letter in‐
crease in VA during the first 2 years of the studies Patients that did not receive anti-VEGF
therapy in those trials had worse outcomes. During the first year of the HORIZON study
and the third year of the original trials, there was a 5.1-letter loss The initial VA gain de‐
creased by a mean of 8 letters with less frequent dosing in years 3 and 4. During the as need‐
ed dosing phase, the mean number of injections in the group initially treated with
ranibizumab was 3.6. compared to 4.2 injections for patients that were treated with sham in
the original trials.
The results of the HORIZON trial demonstrate that a delay in the initiation of treatment is
associated with poorer visual outcomes and continued but less frequent dosing in years 3
and 4 was associated as well with visual decline [37].
PRN regimen of ranibizumab guided by monthly BCVA and other ophthalmic examina‐
tions, as detailed before, appears effective in sustaining the BCVA gained with 12 monthly
injections with a significant lower number of injections during the extension phase [38].
Each one of these studies evaluated PRN regimens and had its own retreatment criteria,
most of them retreated patients with a 100 μm increase in CRT from the thinnest measure‐
ment, and/or a Decreased VA >5 letters compared with VA score from the previous sched‐
uled study visit, but each study had its particular criteria, and follow up regimen. All those
studies mentioned previously have used the Time Domain OCT which is less accurate than
the Spectral Domain OCT (SD-OCT) – therefore re-treatment criteria usually used the 100
microns increase in thickness. Nowadays by using the SD OCT, residual or recurrent fluid
which is less than 100 microns in height can be detected, so patients are re-treated earlier –
which may account for a better visual outcome using the PRN regimen. Strengths of PRON‐
TO and SUSTAIN include monthly follow-up, but the PRONTO trialconsists of only a small
cohort of patients. The SAILOR trial is the largest, but mandated only quarterly follow up
visits. Overall, these studies support frequent follow up and individualized retreatment to
achieve the best visual acuity gains with the as-needed treatment regimen as an alternative
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to the traditional monthly treatments used in the ANCHOR and MARINA trials. Further‐
more, the CATT study (detailed later) showed that ranibizumab given as needed with
monthly evaluation had effects on vision that were equivalent to those of ranibizumab ad‐
ministered monthly.
4.2. Ranibizumab: Treat-and-extend regimen
Treat-and-extend dosing regimen was first described by Freund et al. for the treatment of
retinal angiomatous proliferation with an anti-VEGF agent. It involved increasing intervals
between intravitreal injections up to 10 weeks as long as no fluid is present on OCT. If fluid
is present, the interval between treatments is shortened[39].The treat-and-extend regimen is
quite variable in terms of treatment criteria, which can include vision loss and/or macular
hemorrhage [39], and the time between treatment, which can extend up to 12 weeks [40, 41].
Unfortunately, there are no large, randomized, prospective trials that investigated the effica‐
cy of this regimen compared to the PRN protocol.
Oubraham et al. compared two ranibizumab retreatment strategies; as-needed (PRN) and
treat-and-extend, in a retrospective review of 90 patients, 52 in the PRN group, and 38 in the
treat-and-extend group. Their treatment regimen included 3 loading doses monthly for the
first three months in both groups, and the decision to re-treat was based only on the exis‐
tence of fluid on OCT They found that at one year, mean gain in VA was greater in the treat-
and-extend group than in the PRN (+10.8 versus +2.3 letters, resp.). Eyes in the treat-and-
extend group received significantly more injections (7.8 versus 5.2). Patients in the PRN
group were followed every 4-5 weeks and the number of follow-up visits was similar in
both groups (8.5 versus 8.8) [40].
Gupta et al. published a retrospective case series of 92 eyes treated with the treat-and-extend
ranibizumab regimen. After 2 years, 32% had gained at least3 lines of vision and received
8.36 and 7.45 injections during the first and second years, respectively. In his study, this reg‐
imen was associated with fewer patient visits, injections, and direct annual medical costs
compared with monthly injections [41].
4.3. Bevacizumab: As-needed regimen
The ABC trial is a prospective, double-masked, multicenter, randomized-controlled trial that
included 131 patients randomized to 3 loading doses of bevacizumab at 6-week intervals fol‐
lowed by as-needed treatment at six week intervals or an alternate treatment atthe start of
the trial (PDT, pegaptanib, or sham). Thirty-two percent of patients in the bevacizumab
group gained at least15 letters with a mean VA increase of 7 letters vs a mean decrease of 9.4
letters in the alternate group. The median number of injections during the 12 months was 7
injections [42].
Other smaller, retrospective studies note a substantial improvement in VA using a protocol
of three loading doses of bvacizumab followed by a PRN regimen, based mostly on OCT
findings [43, 44].
Age-Related Macular Degeneration - Etiology, Diagnosis and Management - A Glance at the Future172
Several retrospective studies demonstrated stabilization or improvement in VA following
PRN treatment regimen with bevacizumab without a loading phase [45, 46]. One prospec‐
tive, open-label, nonrandomized clinical study reported a mean VA gain of 8.6 letters in 51
eyes after their second year of PRN bevacizumab treatment with a mean of only 1.5injec‐
tions given during year 2 [47].
4.4. Bevacizumab: Treat-and-extend regimen
Gupta et al. retrospectively reviewed 74 eyes of 73 patients with treatment-naive nvAMD.
The patients were treated monthly with intravitreal bevacizumab until no intraretinal or
subretinal fluid was observed on OCT. The treatment intervals then were lengthened se‐
quentially by 2 weeks until signs of exudation recurred and then was reduced accordingly
to maintain an exudation-free macula. Main outcomes measured included mean change
from baseline visual acuity, proportion of eyes losing fewer than 3 and gaining 3 or more
Snellen visual acuity lines at 1 year of follow-up, annual mean number of injections, OCT
(Zeiss stratus) mean central retinal thickness change from baseline, mean maximum period
of extension, adverse events, and mean direct annual medical cost. The mean follow-up pe‐
riod was 1.41 years. Mean Snellen VA improved from 20/230 at baseline to 20/109 at 12
months (P <.001) and 20/106 at 24 months (P <.001). The mean number of injections over the
first year was 7.94. The mean OCT central retinal thickness decreased from 316 to 239 μm at
12 months (P <.001). The mean direct medical cost over the first year was $3493.85.
The treat and-extend regimen in their study, was associated with significant visual improve‐
ments with fewer patient visits and injections along with lower costs when compared to the
MARINA, ANCHOR, and PrONTO protocols [48].
5. Comparison of AMD treatment trials (CATT and IVAN trials)
Several retrospective studies have tried to evaluate the efficacy of ranibizumab as compared
to bevacizumab, however they were not powered enough to show the differences in efficacy
or safety between the 2 drugs. The CATT and the IVAN trials are two prospective large
scale randomized controlled trials that compared the two drugs in different regimens of
treatment. The CATT trial is a multicenter, single-blind, non-inferiority trial that collectively
enrolled 1208 patients with nvAMD [49]. Patients were randomized to 4 treatment groups:
monthly bevacizumab, monthly ranibizumab, as-needed bevacizumab and as needed rani‐
bizumab. In the as needed groups, retreatment was performed if at least one of the follow‐
ing criteria was met: fluid present on Time Domain OCT, decreased VA as compared to
previous exam, new or persistent hemorrhage detected on clinical exam, or dye leakage or
increased lesion size visible on fluorescein angiography. The primary outcome measure was
mean change in VA at one year. The results at 12 months showed that Bevacizumab admin‐
istered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 let‐
ters gained, respectively. Bevacizumab administered as needed was equivalent to
ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as need‐
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ed was equivalent to monthly ranibizumab, although the comparison between bevacizumab
as needed and monthly bevacizumab was inconclusive. Ranibizumab as-needed was found
to be equivalent to monthly ranibizumab, but the comparison between bevacizumab as-
needed and monthly ranibizumab was inconclusive [49]. This could be due to the less dura‐
ble treatment effect of bevacizumab in a subgroup of patients [50]. Ranibizumab given as
needed was equivalent to bevacizumab given monthly. The comparison between bevacizu‐
mab given as needed and ranibizumab given monthly was also inconclusive.
The  mean decrease  in  central  retinal  thickness  was  greater  in  the  ranibizumab-monthly
group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance)
Although  not  powered  sufficiently  to  compare  adverse  event  rates  associated  with  the
two  drugs,  the  rates  of  death,  arteriothrombotic  events,  and  venous  thrombotic  events
were similar for patients receiving bevacizumab or ranibizumab. The rate of serious sys‐
temic adverse events, primarily hospitalizations, was higher among the patients who had
received bevacizumab, but rates of adverse events did not increase with increased expo‐
sure to the drug [49].
At 1 year,  patients initially assigned to monthly treatment were reassigned randomly to
monthly  or  as-needed treatment,  without  changing the  drug assignment[51]  The 2  year
results  demonstrate  that  among patients  receiving monthly  injections  for  2  years,  mean
gain  in  visual  acuity  was  similar  for  both  drugs  (bevacizumab-ranibizumab  difference,
-1.4 letters;  95% confidence interval  [CI],  -3.7 to 0.8;  P = 0.21).  However mean gain was
greater for monthly than for as-needed treatment (difference, -2.4 letters;  95% CI, -4.8 to
-0.1;  P = 0.046).  The proportion of patients without fluid on OCT ranged from 13.9% in
the bevacizumab-as-needed group to 45.5% in the ranibizumab monthly group (drug, P =
0.0003; regimen, P < 0.0001).  Switching from monthly to as-needed treatment in the sec‐
ond year resulted in greater mean decrease in vision during year 2 (-2.2 letters; P = 0.03)
and  a  lower  proportion  without  fluid  (-19%;  P  <  0.0001).  Rates  of  death  and  arterio‐
thrombotic events were similar for both drugs (P > 0.60). The proportion of patients with
1 or more systemic serious adverse events was higher with bevacizumab than ranibizu‐
mab  (39.9%  vs.  31.7%;  adjusted  risk  ratio,  1.30;  95%  CI,  1.07-1.57;  P  =  0.009),  even
thoughmost of the excess events have not been associated previously with systemic ther‐
apy targeting vascular endothelial growth factor (VEGF) [51].
The first year results from an NIHR Health Technology Assessment (HTA) programmed
funded trial, IVAN (Inhibit VEGF in Age related choroidal Neovascularization) were recent‐
ly published [52]. The trial compared the efficacy of ranibizumab vs bevacizumab in 610
subjects with nvAMD from 23 hospitals and academic institutions in the UK. In addition
blood samples were repeatedly evaluated for the VEGF concentration in the plasma. Pa‐
tients received injections of the drug into the affected eye every month for the first three
months. Groups were then subdivided to receive either injections at every visit thereafter
namely the continuous group or only if the specialist decided there was persistent disease –
namely the discontinuous group. Whenever re-treatment was performed the patient re‐
ceived a series of 3 monthly consecutive injections as opposed to 1 injection given in the
CATT. After 12 months the comparison between the two drugs was inconclusive (-1.99 let‐
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ters in favor of the Ranibizumab, 95% confidence interval [CI], -4.04 to 0.06). Discontinuous
treatment was equivalent to continuous treatment (-0.35 letters; 95% CI, -2.40 to 1.70). Mena
foveal total thickness did not differ by drug, but was 9% less using the continuous treatment
(geometric mean ratio [GMR], 0.91; 95% CI, 0.86 to 0.97; P = 0.005). Fewer participants re‐
ceiving bevacizumab had an arteriothrombotic event or heart failure (odds ratio [OR], 0.23;
95% CI, 0.05 to 1.07; P = 0.03). There was no difference between drugs in the proportion of
subjects experiencing a serious systemic adverse event (OR, 1.35; 95% CI, 0.80 to 2.27; P =
0.25). Serum VEGF levels were found to be significantly lower in subjects treated with beva‐
cizuamb compared to ranibizumab (GMR, 0.47; 95% CI, 0.41 to 0.54; P<0.0001) and higher
with discontinuous treatment compared to continuous treatment (GMR, 1.23; 95% CI, 1.07 to
1.42; P = 0.004). These results clearly indicate the higher systemic exposure to bevacizumab
compared with ranibizumab. Researchers concluded that the comparison of VA at 1 year be‐
tween bevacizumab and ranibizumab was inconclusive. Visual acuities with continuous and
discontinuous treatment were equivalent. Other outcomes are consistent with the drugs and
treatment regimens having similar efficacy and safety.
The results of the second year of the IVAN trial and others like the VIBERA (Germany),
EQUAL (Netherlands) and MANTA (Austria) studies [53-55] are about to be published in
the coming future.
6. Management of nonresponders
As many as 10% of patients demonstrate a significant loss of vision in spite of 2 years of
monthly  anti-VEGF  therapy  [9,  20].  Within  this  group  of  individuals  exist  those  who
progress to disciform scar, RPE tear, massive subretinal hemorrhage, geographic atrophy,
and  in  addition  eyes  that  demonstrate  persistent  macular  fluid/blood  and  leakage  on
OCT and fluorescein angiography associated with vision loss.  This subgroup of patients
is  referred  to  as  anti-VEGF non-responders.  This  variability  in  anti-VEGF treatment  re‐
sponse can be attributed to more aggressive forms of nvAMD, including retinal angioma‐
tous  proliferation  (RAP),  tachyphylaxis  to  anti-VEGF  drugs,  mimics  of  wet  AMD  [56],
and genetic differences among patients [57, 58].
The therapeutic approach in these patients include alternating bevacizumab and ranibizu‐
mab, switching to a newer anti VEGF drug- Eylea, combination therapy which is further dis‐
cussed in the next section, or other treatment options such as brachytherapy and
transpupillary thermotherapy.
6.1. Combination therapy
Since the development and progression of nvAMD involve pro-angiogenic factors, vascular
permeability molecules, and inflammatory proteins, targeting only one component of this
process may be insufficient and temporary, as shown by the data presented above. Anti
VEGF agents are very effective in halting vascular leakage, but it has shown to be a tempo‐
rizing treatment, and there is an increased need for a treatment with longer efficacy dura‐
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tion..The ideal combination therapy regimen would provide a longer-lasting treatment
effect in addition to potentially being more or equally efficacious to monotherapy alone.
The main combination therapies are further discussed.
6.1.1. PDT+ anti VEGF
SUMMIT is a clinical trial program that includes three similarly designed, controlled studies
to further examine the safety, efficacy, and treatment burden of combination therapy with
PDT and ranibizumab compared with ranibizumab alone: DENALI in the USA, and Cana‐
da, examining verteporfin PDT in combination at both standard- and reduced-fluence light
doses; MONT BLANC in Europe, examining verteporfin PDT in combination at standard-
fluence light dose only, and an Asian study (EVEREST) which is designed to compare stand‐
ard fluence PDT combined with ranibizumab and ranibizumab monotherapy in the
treatment of polypoidal choroidal vasculopathy (PCV). Twelve-month results of the MON‐
TBLANC study showed that combining standard-fluence PDT with ranibizumab 0.5mg re‐
sults in VA improvement that is noninferior to a ranibizumab monotherapy regimen with
three ranibizumab-loading doses followed by injections on a monthly PRN basis (non-inferi‐
ority margin of 7 letters There was no significant difference between the two treatment arms
with regard to proportion of patients with a treatment-free interval of at least three months
duration after month 2. Adverse event incidence was similar between treatment groups
[59].As monotherapy is not inferior to the combination; they concluded that monotherapy
should be the preferred treatment.
Twelve-month results of the DENALI study showed that combining PDT with ranibizumab
in a regimen that consists three ranibizumab loading doses followed by additional injections
on a monthly PRN basis and PRN PDT every 3 months can improve VA at month 12 in pa‐
tients with sub foveal CNV secondary to nvAMD [60]. However the combination treatment
was found inferior to the monotherapy with ranibizumab alone. At month 12, patients in the
standard fluence combination group and the reduced fluence combination group gained on
average 5.3 and 4.4 letters from baseline, compared to a more significant gain of 8.1 letters in
the ranibizumab monthly monotherapy group. DENALI did not demonstrate non-inferior
visual acuity gain for PDT combination therapy compared with ranibizumab monthly mon‐
otherapy, meaning the monotherapy with monthly ranibizumab was found superior to the
combination therapy.
Six months results of the EVEREST trial were recently published [61]. At Month 6, verte‐
porfin PDT combined with ranibizumab or verteporfin PDT alone was superior to ranibi‐
zumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%;
P < 0.01);  mean change ± standard deviation in best-corrected visual acuity (letters) was
the highest  in the combination group although not statistically better  than the ranibizu‐
mab monotherapy. There was a mean improvement of 10.9 ± 10.9 letters in the vertepor‐
fin  PDT  +  ranibizumab,  7.5  ±  10.6  letters  in  the  verteporfin  PDT  alone,  and  9.2  ±  12.4
letters  in the ranibizumab monotherapy.  There were no new safety findings with either
drug used alone or in combination. Based on the results of the EVERST we can conclude
that combination therapy of reduced fluence PDT with ranibizumab should be applied in
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cases  of  PCV,  because  this  combined  treatment  yields  the  best  VA  results  and  highest
rate of anatomic closure of the polyps.
6.1.2. Triple therapy
Augustin et al. described a combination therapy involving standard fluence PDT with re‐
duced light duration (70 seconds instead of 83 seconds),with total light dose of 42J/ cm2. Six‐
teen hours after PDT administration patients were taken to the operating room, and
underwent limited vitrectomy followed by intravitreal dexamethasone (800 mcg) and intra‐
vitreal bevacizumab (1.5 mg) injections [62]. Most patients treated with this triple therapy
hadlong-lasting improvement in VA with only one treatment at final follow-up (The mean
follow-up period was 40 weeks (range, 22-60 weeks). Less than one-fourth of the patients
treated with this regimen required additional treatment either with repeat triple therapy or
anti-VEGF alone during the follow-up period [62].
Bakri et al. retrospectively reviewed the treatment benefit in patients receiving a same-day
combination of reduced fluence PDT, intravitreal dexamethasone (200mcg), and intravitreal
bevacizumab (1.25 mg). Patients were either treatment naïve or previously treated. At final
follow-up, patients treated with this regimen showed stable VA and decreased macular
thickness [63].
An average of less than one additional treatment with either repeat triple therapy or anti-
VEGF was required in the treatment of naive group while almost four additional treatments
were required in previously treated patients [63]. No steroid-related complications were not‐
ed in either study [62, 63]. A prospective interventional case series of 17 patients treated
with a same-day regimen of standard fluence PDT, intravitreal bevacizumab(1.25 mg), and
intravitreal triamcinolone (IVTA) (2 mg), was recently published. Patients treated with this
regimen also showed an improvement in VA and reduced central macular thickness [64].
The  Reduced  Fluence  Visudyne  Anti-VEGF  Dexamethasone  in  Combination  for  AMD
Lesions  (RADICAL)  trial  is  a  prospective,  multicenter,  randomized trial  of  combination
therapy for  the treatment  of  wet  AMD that  began in  2008.  Patients  are  randomized in‐
to  four  treatment  arms  including  anti-VEGF  monotherapy  with  ranibizumab,  half-flu‐
ence  PDT  with  ranibizumab,  half-fluence  PDT  with  ranibizumab  and  dexamethasone,
or  quarter-fluence  PDT  with  ranibizumab  and  dexamethasone.  The  dose  of  ranibizu‐
mab used was  0.5  mg and dexamethasone  500  mcg.  Patients  enrolled  in  the  trial  were
followed  for  a  total  of  24  months.  For  the  first  12  months,  patients  were  followed
monthly  with  decision  for  retreatment  made  at  each  visit.  After  12  months,  patients
were  reassessed every  3  months  or  sooner  at  physician’s  discretion.  Patients  in  the  an‐
ti-VEGF  monotherapy  arm  received  mandatory  first  3  monthly  consecutive  injections
followed  by  retreatment  as  needed  thereafter.  Retreatment  with  combination  therapy
was  not  administered  prior  to  8  weeks  interval.  Twelve-month  data  released  by  the
sponsor  [65],  QLT  incorporated,  showed  significantly  fewer  re-treatments  in  all  combi‐
nation  therapy  arms  compared  with  the  groups  of  patients  treated  with  anti-VEGF
monotherapy [65].
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VA  appears  to  equally  improve  among  all  groups,  but  confidence  intervals  varied.  Of
the  three  combination  therapy  arms,  the  triple  therapy  half-fluence  PDT  group  shared
similar  mean visual  improvement  compared with  monotherapy  and had the  fewest  re-
treatments.  After  12  months,  three  retreatments  of  triple  therapy with  half-fluence  PDT
were  required  compared  to  5.1  re-treatments  of  monotherapy  (p<0.001).  Adverse  event
incidence  was  similar  amongst  all  treatment  groups.  The  final  results  of  the  24-months
trial were not published yet.
7. Potential complications of anti VEGF agents
Safety issues with anti VEGF intravitreal injections include local ocular adverse events (AEs)
from the drug or the injection, as well as potential systemic AEs of the drug.
Ocular AEs may be categorized as common but not serious and rare but potentially serious.
The AEs that are considered common but not serious include subconjunctival hemorrhage,
vitreous floaters from medication or vitreous hemorrhage, and discomfort from antiseptic
used to prepare the conjunctiva before the injection(9, 20, 21).
Repeated intravitreal injection of ranibizumab or bevacizumab, over extended time periods,
has been demonstrated to result in a low incidence of serious ocular adverse events. In the
CATT study, endophthalmitis developed after only two of 5449 injections (0.04%) in 599 pa‐
tients treated with ranibizumab, and after only four of 5508 injections (0.07%) in 586 patients
treated with bevacizumab. Uveitis, retinal detachment, retinal vascular occlusion or embo‐
lism, retinal tear, and vitreous hemorrhage each also occurred in less than 1% of patients [49,
50]. Efforts are underway in order to further reduce the incidence of these events, with stud‐
ies evaluating the effect of needle type and injection technique on patient pain levels, vitreal
reflux, and ocular complications [66].
It is unknown if pretreatment antibiotics for several days prior to injection, or only on the
procedure's day is necessary in order to reduce the risk of endophthalmitis. Furthermore, it
is unknown if post treatment antibiotics are necessary on the day of the procedure or there‐
after to reduce this risk furthermore. Although the product insert for ranibizumab indicates
that the administration of the intravitreal injection should include the use of sterile gloves
and a sterile drape, not all physicians agree that these items are necessary to maintain sterile
conditions for the injection. However, all agree that the use of a lid speculum and adminis‐
tration of povidone-iodine to the lids, lashes, and conjunctiva are recommended [67].
Another concern is an allergic reaction to the drug. Since ranibizumab is a recombinant
monoclonal antibody that contains both mouse and human derived segments, some patients
treated with the drug may develop systemic antibodies [8, 20].
In the ANCHOR trial 3.9% of ranibizumab 0.5-mg subjects had developed antibodies to ra‐
nibizumab compared with 0% in the PDT group [20].
In the MARINA trial, after 24 months, 6.3% of subjects treated with ranibizumab 0.5 mg and
1.1% of those in the sham injection group developed antibodies to ranibizumab [8].
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Systemic AEs are a concern, since inhibitors of VEGF injected intravitreally, can penetrate
the general circulation and compromise functions that rely on VEGF outside of the eye, such
as wound healing and the formation of new blood vessels around the heart or brain in cases
of ischemia [68, 69]. Patients with AMD already are at higher risk of cardiovascular disease
than the general population because of their age and the association of AMDwith systemic
hypertension [70], consequently, participants in clinical trialsof VEGF inhibitors were care‐
fully monitored for possible increases in blood pressure, occurrence of myocardial infarc‐
tion/stroke, and nonocular hemorrhages [8, 20].
Among participants in the MARINA trial, approximately16% in both the ranibizumab 0.5
mg and sham injectiongroups developed hypertension [8] and in the ANCHOR treatment
related hypertension was higher in the PDT group (8.4%) than in the ranibizumab group
(6.4%) [20].
In the CATT trial there was no evidence that ranibizumab0.5 mg was associated with in‐
creases in either diastolic or systolic blood pressure [49, 50].
Nonocular hemorrhages include events such as cerebral or gastrointestinal bleeding. In the
ANCHOR trial, non ocular hemorrhage was more frequent in the 0.5-mg ranibizumab
group (6.4%) than in the PDT group (2.1%) [20]. In the MARINA trial, the cumulative fre‐
quency of nonocular hemorrhage by month 24 was 5.5% in the sham injection group com‐
pared with 8.8% in the 0.5-mgranibizumab group [8].
Among participants in the MARINA trial, approximately 16% in both the ranibizumab 0.5
mg and sham injection groups developed hypertension [3].
In the CATT trial Gastrointestinal disorders (e.g., hemorrhage, hernia, nausea, and vomit‐
ing), occurred in 11 (1.8%) ranibizumab-treated and in 28 (4.8%) bevacizumab-treated pa‐
tients (P = 0.005) [51].
With respect to cardiovascular or cerebrovascular events, during the ANCHOR trial, 1 sub‐
ject in the PDT group (0.7%) and 3 subjects in the ranibizumab 0.5-mg group (2.1%) devel‐
oped nonfatal myocardial infarctions, although the events did not occurshortly after
treatment. [20]. The frequency of stroke (1 in each group) and cerebral infarction (0 in each
group) in the ANCHOR trial were too low to draw meaningful conclusion [20].
At 24 months, the overall frequency of cardiovascular systemic events in the MARINA trial
was similar in the0.5-mg ranibizumab and sham injection groups [8]. Therewere only small
differences in the frequency of thromboembolic events between the sham injection group
(3.8%) and the ranibizumab 0.5-mg group (4.6%) [8]. The frequency of death (2.5%) was the
same in the ranibizumab 0.5-mgand sham injection groups [8]. Two individuals in each
group died of stroke.
There was no significant difference in the frequency of myocardial infarction between the 2
treatment groups in the SAILOR trial [36].
In the CATT trial at 2 years, 5.3% assigned to ranibizumab and 6.1% assigned to Bevacizu‐
mab had died (P = 0.62). The proportion of patients with arteriothrombotic events was simi‐
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lar in the ranibizumab-treated patients (4.7%) and in the bevacizumab-treated patients 5.0%;
(P = 0.89). Venous thrombotic events occurred in 3 (0.5%) ranibizumab-treated patients and
in 10 (1.7%) bevacizumab-treated patients (P = 0.054) [51].
One or  more  serious  systemic  adverse  events  occurred in  255  patients  (21.5%),  with  53
(17.6%)  in  the  ranibizumab-monthly  group,  64  (22.4%)  in  the  bevacizumab-monthly
group,  61  (20.5%) in  the  ranibizumab-as-needed group,  and 77 (25.7%) in  the bevacizu‐
mab-as-needed group (P = 0.11 by the chi-square test). Hospitalizations accounted for 298
of  the  370  individual  serious  systemic  adverse  events  (80.5%).  When  dosing-regimen
groups were combined, the proportions of patients with serious systemic adverse events
were 24.1% for bevacizumab and 19.0% for ranibizumab (P = 0.04).  After adjustment for
demographic features and coexisting illnesses at baseline, the risk ratio for bevacizumab,
as compared with ranibizumab, was 1.29 (95% confidence interval, 1.01 to 1.66; P = 0.04).
Patients  treated  as  needed  had  higher  rates  than  patients  treated  monthly  (risk  ratio,
1.20;  95%  CI,  0.98 −1.47;  P  =0.08).  After  excluding  all  events  previously  associated  with
systemic treatment with anti–vascular endothelial growth factor drugs, 170 (28.4%) of ra‐
nibizumab-treated patients  and 202  (34.5%)  of  bevacizumab-treated patients  had experi‐
enced events (P = 0.02) [51].
Although event rates for these cerebrovascular or cardiovascular events seem to be low with
ranibizumab, ophthalmologists should ensure that patients understand the theoretic poten‐
tial for these risks. Additional studies over time may help to refine understanding of the
magnitude, if any, of this risk.
In the recently published IVAN trial at 12 months, 6 participants (1.9%) in the ranibizu‐
mab group and 5 (1.7%) in the bevacizumab group (P  = 0.81) had died; 5 (1.6%) had re‐
ceived  continuous  and  6  (2.0%)  discontinuous  treatment  (P  =  0.74)  [52].  Fewer
participants treated with bevacizumab compared with ranibizumab had an arteriothrom‐
botic event or heart failure (0.7% vs. 2.9%; odds ratio, 0.23; 95% CI, 0.05to 1.07; P = 0.03),
but no difference between treatment regimens was found (P = 0.34). One or more serious
systemic adverse events occurred in 30 (9.6%) in the ranibizumab group and 37 (12.5%)
in the bevacizumab group (P = 0.25). Similarly, 30 (9.7%) in the continuous and 7 (12.3%)
in the discontinuous group had ≥1 serious systemic adverse events (P  = 0.32). More than
10 participant-specific events occurred in 3 MedDRA categories: cardiac disorders, surgi‐
cal  or  medical  procedure,  and any  other  class  (available  at  http://aaojournal.org).  Com‐
parisons  by  drug and regimen for  cardiac  disorders  and surgical  or  medical  procedure
showed  no  differences  (P≥0.46).  One  case  of  severe  uveitis  developed  after  1  injection;
there was 1 reported traumatic cataract and 3 retinal pigment epithelial tears. Five “oth‐
er” ocular events were each reported once.
7.1. Safety of Bevacizumab
Data on the safety of intravitreal bevacizumab are more limited than data on Ranibizumab
safety, due to the lack of large multicenter trials performed with Bevacizumab. The results
of the CATT and IVAN trials were previously presented.
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8. New anti VEGF agents under investigation
8.1. RNA Interference (SIRNA)
SIRNA stands for short interfering RNA. SIRNAs are 21 to 25 nucleotide-long double-stranded
RNA molecules capable of destroying a corresponding target messenger RNA with high selec‐
tivity and efficacy [71]. This leads to post transcriptional gene silencing (PTGS).
SIRNAs work intracellularly, where they are incorporated into a protein complex called
RNA-induced silencing complex (RISC) [71]. The RISC has RNA helicase activity, which un‐
winds the two strands of RNA. The strand of the siRNA that becomes associated to the RISC
leads the complex to selectively cleave and degrade messenger RNA molecules containing a
complementary sequence. The siRNA is engineered to match the protein encoding nucleo‐
tide sequence of the target messenger RNA. Since the translation of messenger RNA into
proteins is an amplification step, destroying it is a very potent method of inhibiting protein
function.
SIRNA-027 (SIRNA Therapeutics, Inc.) is a short interfering RNA that targets the VEGF re‐
ceptor 1 (VEGFR-1).Animal experiments have shown that both intravitreous and periocular
injections of siRNA directed against VEGFR1 lead to a substantial reduction of VEGFR1
messenger RNA levels [71-72].
The siRNA suppressed the development of CNV at rupture sites in Bruch’s membrane and de‐
creased retinal neovascularizationin mice with oxygen-induced ischemic retinopathy [72-73].
Acuity Pharmaceuticals has also produced a siRNA called Cand5 or Bevasiranib that targets
the messenger RNA of the VEGF protein itself. Animal models have shown prevention of
CNV development after laser-induced injury [72].
Bevasiranib sodium was developed for intravitreal administration. Following intravitreal in‐
jection, bevasiranib is well distributed within the eye and localizes to the retina [72, 73].
Preliminary results of Phases I and II clinical trials of bevasiranib have shown promising re‐
sults for the treatment of nvAMD and diabetic macular edema. There are various studies of
different phases underway (the COBALT studies although recruitment was stopped). A
phase III study evaluating the combination of bevasiranib and ranibizumab in nvAMD (the
CARBON study) is currently underway.
The purpose of this study is to compare intravitreal bevasiranib sodium as maintenance
therapy for AMD following initiation with three monthly doses of ranibizumab. Preliminary
clinical results indicate that the effects of bevasiranib do not appear until six weeks after the
initiation of treatment, which suggests that combination therapy with anti VEGF drug might
be justified. The late effect of bevasiranib might be linked to its mechanism of action, since
bevasiranib inhibits the synthesis of new VEGF, and does not eliminate existing VEGF, a di‐
rect anti-VEGF agent may be required to neutralize VEGF already present in the eye before
inhibition of new VEGF synthesis. Preliminary results of the carbon and cobalt studies sug‐
gested that over 30% of patients on combination ranibizumab-bevasiranib achieve an im‐
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provement of at least three additional lines of VA than those on ranibizumab alone. The
safety and efficacy of this combination awaits the full results of the ongoing clinical trials.
However, the lack of available data from randomized placebo-controlled or comparative
studies makes it difficult to evaluate the role of bevasiranib in nvAMD therapy. It is clear
from experimental and preclinical studies that anti-VEGF siRNA is capable of down regulat‐
ing VEGF production, a key goal of anti-VEGF therapy [72].
In summary, bevasiranib exploits an interesting technology [72, 73] and may be a useful ad‐
dition to the currently available drugs used to treat wet AMD.
8.2. Tyrosine kinase inhibitors
VEGF A signals through two VEGF receptors [7, 10]. VEGF R consist of protein-tyrosine kin‐
ases (VEGFR-1, VEGFR-2, and VEGFR-3) and two non-protein kinase coreceptors (neuropi‐
lin-1 and neuropilin-2) [10]. New drugs targeting these tyrosine kinases are being
investigated.
Vatalanib (PTK787; Novartis)- Vatalanib [74] is a potent tyrosine kinase inhibitor with good
oral bioavailability and activity against the VEGFR family, PDGFRβ and c-Kit receptor kin‐
ases. Preclinical studies [74] suggest that vatalanib induces dose-dependent inhibition of
VEGF-induced angiogenesis. A phase I/II trial, ADVANCE [75], to evaluate the safety and
efficacy of oral vatalanib combined with PDT with verteporfin in 50 patients has been com‐
pleted, but the data have not yet been published in a peer-reviewed journal.
Pazopanib (GW786034; GlaxoSmithKline)- Pazopanib [76] is a second-generation tyrosine
kinase inhibitor against all VEGFR, PDGFRα, PDGFRβ, and c-kit. A phase I clinical trial us‐
ing pazopanib as eye drops in 38 healthy volunteers has successfully demonstrated its safety
and tolerability. Subsequently, a phase II trial [77] to evaluate its pharmacodynamics, phar‐
macokinetics and safety has been completed, but the data have not yet been published in a
peer-reviewed journal.
8.3. Anti-VEGFR vaccine therapy
This is an immunologic approach to combat CNV. A recent report demonstrated CD8+ cyto‐
toxic T lymphocyte (CTL)-mediated regression of physiologic and pathologic retinal neovas‐
cularization [78], thus a possible immunologic therapy for CNV was suggested. It was
approved by an animal model [79] which showed that CNV can regress by inducing cellular
immunity specific for VEGFR-2.
More recently, a phase I study [80] of anti-VEGFR vaccine therapy has been recruiting par‐
ticipants. The patients will be vaccinated once a week for 12 weeks. On each vaccination
day, VEGFR-1 peptide (1 mg) and VEGFR-2 peptide (1 mg) mixed with Montanide ISA 51
will be administered by subcutaneous injection. The study will evaluate the safety and toler‐
ability as well as the immunological and clinical response of the vaccine therapy to treat‐
ment of nvAMD.
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8.4. Anti inflammatory mediators
As mentioned before, both angiogenic and inflammatory processes are involved in nvAMD,
new therapeutics targeting the inflammatory process, besides steroids are being investigated
POT-4 (Potentia Pharmaceuticals)- POT-4 [81] is a peptide capable of binding to human
complement factor C3 (C3). As C3 is a central component of all known complement activa‐
tion pathways, its inhibition effectively shuts down all downstream complement activation
that could otherwise lead to local inflammation, tissue damage and up-regulation of angio‐
genic factors such as VEGF.
A phase I single escalating dose study [82] has just released its first results, which indicate
that POT-4 IVT is safe, and the data accumulated so far support the continued investigation
of POT-4 for the treatment of both dry and wet AMD with a larger randomized phase II trial
to further define its efficacy profile.
ARC1905 (Ophthotech Corp.) -ARC1905 [81] is an anti-C5 aptamer, which prevents the for‐
mation of key terminal fragments (C5a and C5b-9) by inhibiting human complement factor
C5 (C5). C5a fragment is an important inflammatory activator inducing vascular permeabili‐
ty, recruitment and activation of phagocytes. C5b-9 is involved in the formation of mem‐
brane attack complex (C5b-9), which initiates cell lysis [81]. Thus by inhibiting these C5-
mediated inflammatory, ARC1905 might be beneficial in wet AMD.
A phase I study [83] to evaluate the safety, tolerability, and pharmacokinetic profile of mul‐
tiple doses of ARC1905 IVT in combination with multiple doses of Lucentis has been com‐
pleted, but the data have not yet been published in a peer-reviewed journal.
OT-551 (Othera)- OT-551 [84], an Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop
has the potential for chronic treatment of the dry form of age-related macular degeneration.
A phase I trial [84] demonstrated that when the compound is added to Lucentis or Avastin treat‐
ment, there is a synergistic effect in patients with wet AMD. A pilot study [85] of participants
with bilateral geographic atrophy is designed to characterize the effect of 0.45% concentration of
OT-551 eye drops on the progression of geographic atrophy area over a two-year period.
8.5. AdPEDF - Fovista (GenVec)
Pigment epithelium-derived factor (PEDF) is one of the most potent antiangiogenic proteins
found in humans, which were shown to inhibit VEGF-induced proliferation, migration of
microvascular endothelial cells, reduce VEGF-induced hypermeability and cause vessel re‐
gression in established neovascularization [86]. AdPEDF uses a DNA carrier, to deliver the
PEDF gene, resulting in the local production of AdPEDF in the treated eye.
A phase I escalating-dose clinical trial [87] in patients with nvAMD was completed. Three to
six months after a single injection, it suggested that 50–94% of patients had a stabilization or
improvement in lesion size from baseline, suggesting that antiangiogenesis may last for sev‐
eral months after a single IVT. there were no dose-limiting toxicities or drug-related severe
adverse events reported. Further studies investigating the efficacy of AdPEDF in patients
with wet AMD are under way.
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Trial No. of patients Injection protocol Drug, dosage, control Results
VISION 1186 IVT every 6 weeks Pegaptanib; 0.3/1.0/3.0mg-Sham
31%–37% stable vision,
4%–6%gained "/>3
lines (12 months)
MARINA 716 IVT monthly Ranibizumab; 0.3/0.5mg-sham
95% stable vision, 26%–
34% gained"/>3 lines
(12 months)
ANCHOR 423 IVT monthly
Ranibizumab; 0.3/0.5
mg-Sham + PDT every
3 months if needed
96%Stable vision,35%–
40% gained"/>3lines
(12 months)
FOCUS 162 IVT monthly+PDT Ranibizumab; 0.5 mg-PDT every 3 months 90% stable vision
HORIZON 853 IVT monthly Ranibizumab; 0.5 mg
Mean loss of vision 2–5
letters, 3%
gained "/>3 lines, 7%–
14% lost "/>3 lines (12
months)
PIER 183
IVT monthly x 3, re-
treatment
every 3 months
Ranibizumab; 0.3/0.5
mg-sham
83%–90% stable vision,
12%–13% gained "/
>3lines (12 months)
PRONTO 37
IVT monthly x 3, re-
treatment
as needed (9.9 injections
over
24 months)
Ranibizumab; 0.5 mg 43% gained "/>3 lines(24 months)
SUSTAIN 513
IVT monthly x 3, re
treatment as needed
(5.3 injections for
"naïve" patients over 12
months)
Ranibizumab; 0.3/0.5
mg
Mean BCVA increased
steadily from baseline to
month 3 to reach +5.8
letters, decreased
slightly from month 3 to
6, and remained stable
from month 6 to 12,
reaching +3.6 at month
12
CLEAR-IT 51 IVT single
Aflibercept;
0.05/0.15/0.5/1.0/2.0/4
.0 mg
95% stable vision, 50%
of 2.0/4.0 mg
group gained "/>3 lines
(3 months)
VIEW1
VIEW2
1217
1240
VTE 0.5 mg monthly
(0.5q4wk), VTE 2 mg
monthly (2q4wk),VTE 2
mg every two months
(2q8wk), or ranibizumab
0.5mg monthly (Rq4wk)
Aflibercept (VTE);0.5/2.0
mg-Ranibizumab;0.5 mg
All VTE groups were
noninferior to
ranibizumab.
Table 1. Summary of main clinical trials on anti VEGF treatment for AMD
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9. Conclusion
Over the past decade, the treatment of nvAMD improved dramatically with the discovery of
anti-VEGF agents that have enabled patients not only to stabilize the vision but to improve
and regain vision in this potentially blinding disease.
With the goal of maximizing VA and minimizing the frequency of intravitreal injections and
associated risks of treatment, evidence-based management of wet AMD has evolved into in‐
dividualized anti-VEGF therapy with frequent follow up and retreatment. As a safer and
more cost-effective alternative to the traditional monthly treatments used in the ANCHOR
and MARINA trials, two individualized anti-VEGF treatment regimens have been descri‐
bed, but neither has been proven superior to date: as-needed (or “PRN”) therapy and the
treat-and-extend strategy. Despite a paucity of evidence comparing the as-needed versus the
treat-and extend treatment regimens, a possibility exists that the treat and extend regimen
will prove to be the most efficacious, cost-saving, and preferred protocol. The current evi‐
dence based treatment strategy for the management of wet AMD supports the use of either
bevacizumab or ranibizumab either monthly or with a more individualized treatmentstrat‐
egy with close followup. As second generation anti-VEGF agents become available and the
stress on our healthcaresystems intensifies, increasingly efficacious and costconscioustreat‐
ment strategies will be essential.
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